3C-P

In today's world, 3C-P is a topic of constant debate and controversy. Whether it's politics, technology, culture or society, 3C-P has captured the attention of people of all ages and backgrounds. In this article, we will explore different facets related to 3C-P and analyze its impact on our lives. From the latest scientific advances to the opinions of experts in the field, we will seek to shed light on the topic and provide a complete and enriching overview for our readers. Through interviews, research, and concrete examples, we hope to shed light on 3C-P and help our readers better understand its relevance in today's world.

3C-P
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • 1-(3,5-Dimethoxy-4-propoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23NO3
Molar mass253.342 g·mol−1
3D model (JSmol)
  • CC(N)Cc1cc(OC)c(OCCC)c(c1)OC
  • InChI=1S/C14H23NO3/c1-5-6-18-14-12(16-3)8-11(7-10(2)15)9-13(14)17-4/h8-10H,5-7,15H2,1-4H3 checkY
  • Key:KKMCHCCXGKYEKJ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

3C-P, also known as 4-propoxy-3,5-dimethoxyamphetamine, is a psychedelic phenethylamine. It has structural and pharmacodynamic properties similar to the drugs mescaline, proscaline, and amphetamine. Little information exists on the human pharmacology of 3C-P, but a psychedelic dosage appears to be 20–40 mg,[1] and is accompanied by stimulant and psychedelic effects such as visual enhancement and distortion.[medical citation needed] It can be synthesized from syringaldehyde by reaction with n-propyl iodide followed by condensation with nitroethane and reduction.[2] 3C-P acts as a serotonin 5-HT2 receptor agonist.[3]

See also

References

  1. ^ Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species" (PDF). Neuropharmacology. 167: 107933. doi:10.1016/j.neuropharm.2019.107933. PMC 9191653. PMID 31917152. Table 4 Human potency data for selected hallucinogens.
  2. ^ Trachsel D (September 2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate". Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
  3. ^ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC 10724237. PMID 38102107.


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.